AS the head of the ASX-listed anti-infectives house Biotron, Dr Michelle Miller has experienced first-hand the impact of the pandemic on the listed healthcare sector – for better and for worse.
It was an artificial time for biotechs, says Bianca Ogden, of Platinum Asset Management. Peter Braig
